The perceived waning of biologics in severe asthma
Open Access
- 25 September 2023
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 219, 107416
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Phase 3 Study of Reslizumab in Patients With Poorly Controlled AsthmaChest, 2016
- Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncologyClinical Pharmacology & Therapeutics, 2015
- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challengesNature Reviews Rheumatology, 2015
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Monoclonal Antibody Pharmacokinetics and PharmacodynamicsClinical Pharmacology & Therapeutics, 2008
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The Mechanism of Action of Suggestion in the Induction of Acute Asthma AttacksPsychosomatic Medicine, 1969